Cresco Labs Announces the Opening of its First Four Sunnyside* Dispensaries in New York and the Launch of its Medical Cannabis Delivery Program in the New Hartford Area

CHICAGO–([1])–Cresco Labs[2] (CSE:CL)(OTCQX:CRLBF) (“Cresco” or “the Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the conversion of four dispensaries to Cresco’s nationwide retail brand, Sunnyside*, in the Williamsburg neighborhood in Brooklyn, Huntington Station, New Hartford and Bardonia, New York. Cresco also launched today a home delivery service for medical cannabis patients in the New Hartford area of New York. Patients can place orders for home delivery for a variety of products including vape pens and cartridges, topical creams, oral tinctures and capsules at[3]. Cresco plans to roll out its medical cannabis home delivery program to the three other communities with Sunnyside* locations in the coming months.

These dispensaries in the state of New York are the first stores to be rebranded under Cresco’s national retail brand on the East Coast. Cresco holds one of the 10 vertically integrated cannabis business licenses granted in the state by the New York State Department of Health. Each license gives the operator the right to operate one cultivation facility and four dispensaries in New York.

As we continue to build our national retail brand and consolidate the five dispensary brands we operate around the country under the Sunnyside* name, we remain focused on ensuring that we deliver against the promise of what Sunnyside* stands for—wellness, education and convenience,” said Charlie Bachtell, Cresco Labs CEO and Co-founder. “New York has a growing medical cannabis patient program of more than 114,000 people who look to dispensaries and their cannabis product forms to treat a variety of qualifying conditions and critical illnesses. With Sunnyside*, we aim to provide a best-in-class shopping experience through ongoing education, product availability and technology. The ease of home delivery provides the convenience that many living in New York will appreciate with the benefit of the quality and consistency that regulated, third-party tested, cannabis products can provide. Home delivery plays a critical role in our ecommerce strategy, and we are excited to offer this service to reach medical cannabis patients in our communities with the right products they need.”

Registered medical cannabis patients can place a home delivery order seven days a week at with a minimum order of $80 required for delivery service. Free delivery is available for orders of $150 or more. Distributed from Cresco’s Sunnyside* dispensary in New Hartford, delivery services are available for patients in the following communities: New Hartford, Utica, Marcy, Whitesboro, Oriskany, Clinton, Sauquoit, Frankfurt and Rome.

About Cresco Labs

Cresco Labs is one of the largest vertically-integrated multi-state cannabis operators in the United States. Cresco is built to become the most important company in the cannabis industry by combining the most strategic geographic footprint with one of the leading distribution platforms in North America. Employing a consumer-packaged goods (“CPG”) approach to cannabis, Cresco’s house of brands is designed to meet the needs of all consumer segments and includes some of the most recognized and trusted national brands including Cresco, Remedi and Mindy’s, a line of edibles created by James Beard Award-winning chef Mindy Segal. Sunnyside*, Cresco’s national dispensary brand, is a wellness-focused retailer designed to build trust, education and convenience for both existing and new cannabis consumers. Recognizing that the cannabis industry is poised to become one of the leading job creators in the country, Cresco has launched the industry’s first national comprehensive Social Equity and Educational Development (SEED) initiative designed to ensure that all members of society have the skills, knowledge and opportunity to work in and own businesses in the cannabis industry. Learn more about Cresco Labs at[4].

Forward Looking Statements

This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as, ‘may,’ ‘will,’ ‘should,’ ‘could,’ ‘would,’ ‘expects,’ ‘plans,’ ‘anticipates,’ ‘believes,’ ‘estimates,’ ‘projects,’ ‘predicts,’ ‘potential’ or ‘continue’ or the negative of those forms or other comparable terms. The Company’s forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including but not limited to those risks discussed under “Risk Factors” in the company’s CSE Listing Statement filed with SEDAR; and other factors, many of which are beyond the control of the Company. Readers are cautioned that the foregoing list of factors is not exhaustive. Because of these uncertainties, you should not place undue reliance on the Company’s forward-looking statements. No assurances are given as to the future trading price or trading volumes of Cresco’s shares, nor as to the Company’s financial performance in future financial periods. The Company does not intend to update any of these factors or to publicly announce the result of any revisions to any of the Company’s forward-looking statements contained herein, whether as a result of new information, any future event or otherwise. Except as otherwise indicated, this press release speaks as of the date hereof. The distribution of this press release does not imply that there has been no change in the affairs of the Company after the date hereof or create any duty or commitment to update or supplement any information provided in this press release or otherwise.

1 2 3